Article Text

Download PDFPDF
Guest lectures
GL.04 Bridging the gap between genes and behaviour: the case for neuroimaging genetics
  1. J Roiser

    Jonathan Roiser studied Natural Sciences at Trinity College, Cambridge, as an undergraduate, and remained there for his doctorate in the Department of Psychiatry. His PhD focused on the effects of monoamine depletions on mood and cognitive performance, with a particular emphasis on demonstrating that genetic variation can explain some of the variability commonly observed between individuals in their vulnerability to perturbations of the serotonin system. He then spent a year conducting a pharmacological fMRI study at the National Institute of Mental Health, USA, in patients recovered from depression and controls.

    Following a post-doctoral appointment at the UCL Institute of Neurology, London, where he investigated the neural mechanisms underpinning psychotic phenomena and cognitive impairment in schizophrenia, he was appointed to a faculty post at the UCL Institute of Cognitive Neuroscience. He has published over 40 peer-reviewed papers and his laboratory is currently funded by the Medical Research Council and the British Academy. In 2008 he founded the UCL-NIMH/NINDS Joint Doctoral Training Program in Neuroscience, which he co-directs. His research interests remain focused on understanding the neurobiological basis of psychiatric symptoms, combining behavioural, psychopharmacological and genetic approaches with neuroimaging techniques. In the future he hopes to continue his work on understanding the sources of individual differences in responses to pharmacological treatment in psychiatric conditions, particularly depression and schizophrenia.


In recent years, very large association studies have begun to reveal the contributions of specific common genetic variants in conferring risk for mental illnesses such as autism, schizophrenia and bipolar disorder. However, the size of effect of each individual risk variant has turned out to be surprisingly small (other than for some large structural genetic abnormalities that exist in only very few patients). In the context of very high heritability estimates, which suggest that genetic variation explains a substantial proportion of the variance in risk for psychiatric disease, the lack of many single genetic variants of at least small-to-moderate effect sizes is surprising. This problem has been termed “missing heritability”, and there is some controversy as to its explanation.

An alternative strategy for assessing the influence of genetic variation on risk for psychiatric disease is to consider as the phenotype not a categorical diagnosis, but instead a continuous trait that may be closer to some genetically-influenced process than the diagnosis itself. This strategy of examining “endophenotypes” has yielded some successes in non-psychiatric illness. For example, some of the genes implicated in cardiac arrhythmias were initially identified through an electrocardiogram endophenotype known as the “prolonged QT interval”. Some patients with cardiac arrhythmias were found to have a prolonged QT interval, as were their unaffected first-degree relatives. Ultimately, genetic linkage studies using the prolonged QT interval as an endophenotype successfully identified several risk variants.

The endophenotype approach has not yet been adopted widely in psychiatry. Nonetheless, several candidate endophenotypes have been proposed, including brain imaging measurements. Importantly, several brain imaging measurements conform to a number of the criteria for endophenotypes: they can be heritable; they can differentiate reliably psychiatric patients and non-patients; these differences can occur independent of medication or illness phase; and reliable effects can be identifiable in unaffected first-degree relatives. However, the expense and technical challenge inherent in gathering sufficiently large samples has generally precluded the use of brain imaging methods in large-scale genome-wide association studies to date. Instead, neuroimaging genetics studies have more commonly used the reverse approach, aiming to understand how risk variants for psychiatric disorders might alter brain function in non-psychiatric subjects. While this strategy has yielded some important insights into the mechanisms by which genetic variants affect neural function in healthy individuals, the greatest promise for neuroimaging genetics lies in the identification of new variants that would not have been identified using traditional psychiatric diagnoses as phenotypes.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.